HuGE Literature Finder
Records 1-24
|
Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
Disease markers 2020 2020 8459303. El Otmani Ihsane, El Agy Fatima, El Baradai Sanae, Bouguenouch Laila, Lahmidani Nada, El Abkari Mohammed, Benajah Dafr Allah, Toughrai Imane, El Bouhaddouti Hicham, Mouaqit Ouadii, Ibn Majdoub Hassani Karim, Mazaz Khalid, Benjelloun El Bachir, Ousadden Abdelmalek, El Rhazi Karima, Bouhafa Touria, Benbrahim Zineb, Ouldim Karim, Ibrahimi Sidi Adil, Ait Taleb Khalid, Chbani Lai |
|
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Annals of oncology : official journal of the European Society for Medical Oncology 2019 May 30 (5): 796-803. Santos C, Azuara D, Viéitez J M, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar |
|
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Annals of oncology : official journal of the European Society for Medical Oncology 2019 Mar . Santos C, Azuara D, Viéitez J M, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Salazar R, Aranda |
|
TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Endocrine 2018 Jun . Penna Gustavo C, Pestana Ana, Cameselle José Manuel, Momesso Denise, de Andrade Fernanda Accioly, Vidal Ana Paula Aguiar, Araujo Junior Mario Lucio, Melo Miguel, Fernandes Priscila Valverde, Corbo Rossana, Vaisman Mario, Sobrinho-Simões Manuel, Soares Paula, Vaisman Fernan |
|
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology 2018 01 29 (1): 145-153. Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner |
|
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
BMC cancer 2017 Aug 17 (1): 536. Heppt Markus V, Siepmann Timo, Engel Jutta, Schubert-Fritschle Gabriele, Eckel Renate, Mirlach Laura, Kirchner Thomas, Jung Andreas, Gesierich Anja, Ruzicka Thomas, Flaig Michael J, Berking Caro |
|
Molecular Alterations in Patients with Pulmonary Adenocarcinoma Presenting with Malignant Pleural Effusion at the First Diagnosis.
Acta cytologica 2017 May . Rodriguez Erika F, Shabihkhani Maryam, Carter Jamal, Maleki Zah |
|
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
Gynecologic oncology 2017 Jan . Spreafico A, Oza A M, Clarke B A, Mackay H J, Shaw P, Butler M, Dhani N C, Lheureux S, Wilson M K, Welch S, Zhang T, Yu C, Stockley T, Siu L L, Kamel-Reid S, Bedard P |
|
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
BMC cancer 2017 01 17 (1): 38. Nakayama Izuma, Shinozaki Eiji, Matsushima Tomohiro, Wakatsuki Takeru, Ogura Mariko, Ichimura Takashi, Ozaka Masato, Takahari Daisuke, Suenaga Mitsukuni, Chin Keisho, Mizunuma Nobuyuki, Yamaguchi Kens |
|
Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients.
Cancer 2016 Dec . Kim Dae Won, Haydu Lauren E, Joon Aron Y, Bassett Roland L, Siroy Alan E, Tetzlaff Michael T, Routbort Mark J, Amaria Rodabe N, Wargo Jennifer A, McQuade Jennifer L, Kemnade Jan, Hwu Patrick, Woodman Scott E, Roszik Jason, Kim Kevin B, Gershenwald Jeffrey E, Lazar Alexander J, Davies Michael |
|
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
BMC cancer 2016 Nov 16 (1): 864. Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshia |
|
Multi-region whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma.
Cancer research 2016 May . Harbst Katja, Lauss Martin, Cirenajwis Helena, Isaksson Karolin, Rosengren Frida, Torngren Therese, Kvist Anders, Johansson Maria C, Vallon-Christersson Johan, Baldetorp Bo, Borg Ake, Olsson Håkan, Ingvar Christian, Carneiro Ana, Jonsson Gor |
|
Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
The European respiratory journal 2016 Apr . Mourah Samia, How-Kit Alexandre, Meignin Véronique, Gossot Dominique, Lorillon Gwenaël, Bugnet Emmanuelle, Mauger Florence, Lebbe Celeste, Chevret Sylvie, Tost Jörg, Tazi Abdellat |
|
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Oncotarget 2016 Feb . Feng Qingyang, Wei Ye, Ren Li, Zheng Peng, Yu Yiyi, Ye Qinghai, Ding Jianyong, Chen Jingwen, Chang Wenju, Zhong Yunshi, Zhu Dexiang, Lin Qi, Yang Liangliang, Qin Xinyu, Xu Jianm |
|
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
European journal of cancer (Oxford, England : 1990) 2015 Dec 51 (18): 2792-9. Johnson Douglas B, Menzies Alexander M, Zimmer Lisa, Eroglu Zeynep, Ye Fei, Zhao Shilin, Rizos Helen, Sucker Antje, Scolyer Richard A, Gutzmer Ralf, Gogas Helen, Kefford Richard F, Thompson John F, Becker Jürgen C, Berking Carola, Egberts Friederike, Loquai Carmen, Goldinger Simone M, Pupo Gulietta M, Hugo Willy, Kong Xiangju, Garraway Levi A, Sosman Jeffrey A, Ribas Antoni, Lo Roger S, Long Georgina V, Schadendorf Di |
|
Analysis of somatic mutations in braf, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma.
Molecular medicine reports 2015 Dec . Nascimento Fabrício P, Cardoso Mirian G, Lindsey Susan C, Kunii Ilda S, Valente Flávia O F, Kizys Marina M L, Delcelo Rosana, Camacho Cléber P, Maciel Rui M B, Dias-Da-Silva Magnus |
|
Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor.
Discovery medicine 2015 Oct 20 (110): 231-7. Heppt Markus V, Tietze Julia K, Reinholz Markus, Rahimi Farnaz, Jung Andreas, Kirchner Thomas, Ruzicka Thomas, Flaig Michael J, Berking Caro |
|
Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Pigment cell & melanoma research 2014 Nov 27 (6): 1117-25. Mar Victoria J, Wong Stephen Q, Logan Aleksandra, Nguyen Trung, Cebon Jonathan, Kelly John W, Wolfe Rory, Dobrovic Alexander, McLean Catriona, McArthur Grant |
|
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Thyroid : official journal of the American Thyroid Association 2014 Aug 24 (8): 1256-66. Zou Minjing, Baitei Essa Y, Alzahrani Ali S, BinHumaid Faisal S, Alkhafaji Dania, Al-Rijjal Roua A, Meyer Brian F, Shi Yuf |
|
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.
Blood cancer journal 2014 4 e177. Chen T-C, Hou H-A, Chou W-C, Tang J-L, Kuo Y-Y, Chen C-Y, Tseng M-H, Huang C-F, Lai Y-J, Chiang Y-C, Lee F-Y, Liu M-C, Liu C-W, Liu C-Y, Yao M, Huang S-Y, Ko B-S, Hsu S-C, Wu S-J, Tsay W, Chen Y-C, Tien H |
|
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Proceedings of the National Academy of Sciences of the United States of America 2012 Jul 109 (31): E2127-33. Ohashi Kadoaki, Sequist Lecia V, Arcila Maria E, Moran Teresa, Chmielecki Juliann, Lin Ya-Lun, Pan Yumei, Wang Lu, de Stanchina Elisa, Shien Kazuhiko, Aoe Keisuke, Toyooka Shinichi, Kiura Katsuyuki, Fernandez-Cuesta Lynnette, Fidias Panos, Yang James Chih-Hsin, Miller Vincent A, Riely Gregory J, Kris Mark G, Engelman Jeffrey A, Vnencak-Jones Cindy L, Dias-Santagata Dora, Ladanyi Marc, Pao Willi |
|
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
|
Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): 3530. Oliner K, Peeters M, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem J, Andre T, Wiezorek J S, Patterson S |
|
Clinical correlates of NRAS and BRAF mutations in primary human melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jan 17 (2): 229-35. Ellerhorst Julie A, Greene Victoria R, Ekmekcioglu Suhendan, Warneke Carla L, Johnson Marcella M, Cooke Carolyn P, Wang Li-E, Prieto Victor G, Gershenwald Jeffrey E, Wei Qingyi, Grimm Elizabeth |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: